PFIZERPharmaceuticals
Pfizer Ltd — Profit & Loss Statement
₹4720.50
-0.37%
Pfizer Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 42.05 Cr | 1.43 Cr | 9.03 Cr | 0.00 | — |
| Tax Rate For Calcs | 0.24 | 0.26 | 0.24 | 0.21 | — |
| Normalized EBITDA | 913.36 Cr | 818.30 Cr | 905.72 Cr | 898.38 Cr | — |
| Total Unusual Items | 171.93 Cr | 5.46 Cr | 37.19 Cr | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 171.93 Cr | 5.46 Cr | 37.19 Cr | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Reconciled Depreciation | 60.79 Cr | 62.28 Cr | 105.51 Cr | 115.00 Cr | — |
| Reconciled Cost Of Revenue | 813.06 Cr | 795.23 Cr | 875.65 Cr | 948.03 Cr | — |
| EBITDA | 1.09K Cr | 823.76 Cr | 942.91 Cr | 898.38 Cr | — |
| EBIT | 1.02K Cr | 761.48 Cr | 837.40 Cr | 783.38 Cr | — |
| Net Interest Income | 148.77 Cr | 156.16 Cr | 72.01 Cr | -10.49 Cr | — |
| Interest Expense | 8.41 Cr | 15.41 Cr | 13.39 Cr | 10.49 Cr | — |
| Interest Income | 157.27 Cr | 171.59 Cr | 85.49 Cr | 48.94 Cr | — |
| Normalized Income | 637.72 Cr | 547.30 Cr | 595.77 Cr | 612.56 Cr | — |
| Net Income From Continuing And Discontinued Operation | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Total Expenses | 1.60K Cr | 1.62K Cr | 1.71K Cr | 1.89K Cr | — |
| Rent Expense Supplemental | 0.80 Cr | 0.33 Cr | 0.19 Cr | 0.33 Cr | — |
| Diluted Average Shares | 4.57 Cr | 4.57 Cr | 4.58 Cr | 4.58 Cr | — |
| Basic Average Shares | 4.57 Cr | 4.57 Cr | 4.58 Cr | 4.58 Cr | — |
| Diluted EPS | 167.79 | 120.51 | 136.38 | 133.89 | — |
| Basic EPS | 167.79 | 120.51 | 136.38 | 133.89 | — |
| Diluted NI Availto Com Stockholders | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Net Income Common Stockholders | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Net Income Including Noncontrolling Interests | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Net Income Continuous Operations | 767.60 Cr | 551.33 Cr | 623.93 Cr | 612.56 Cr | — |
| Tax Provision | 248.49 Cr | 194.74 Cr | 200.08 Cr | 160.33 Cr | — |
| Pretax Income | 1.02K Cr | 746.07 Cr | 824.01 Cr | 772.89 Cr | — |
| Other Non Operating Income Expenses | 14.32 Cr | 8.34 Cr | 7.27 Cr | 62.65 Cr | — |
| Special Income Charges | 171.93 Cr | 5.46 Cr | 37.19 Cr | 0.00 | — |
| Other Special Charges | -171.93 Cr | -5.46 Cr | -37.19 Cr | -4.85 Cr | — |
| Net Non Operating Interest Income Expense | 148.77 Cr | 156.16 Cr | 72.01 Cr | -10.49 Cr | — |
| Total Other Finance Cost | 0.09 Cr | 0.02 Cr | 0.09 Cr | 0.21 Cr | — |
| Interest Expense Non Operating | 8.41 Cr | 15.41 Cr | 13.39 Cr | 10.49 Cr | — |
| Interest Income Non Operating | 157.27 Cr | 171.59 Cr | 85.49 Cr | 48.94 Cr | — |
| Operating Income | 681.28 Cr | 577.06 Cr | 708.78 Cr | 720.73 Cr | — |
| Operating Expense | 786.66 Cr | 820.40 Cr | 837.89 Cr | 942.23 Cr | — |
| Other Operating Expenses | 154.09 Cr | 146.52 Cr | 159.95 Cr | 423.56 Cr | — |
| Depreciation And Amortization In Income Statement | 60.79 Cr | 62.28 Cr | 105.51 Cr | 115.00 Cr | — |
| Amortization | 9.96 Cr | 9.96 Cr | 50.32 Cr | 50.32 Cr | — |
| Depreciation Income Statement | 50.83 Cr | 52.32 Cr | 55.19 Cr | 115.00 Cr | — |
| Selling General And Administration | 199.13 Cr | 263.23 Cr | 242.28 Cr | 277.26 Cr | — |
| Selling And Marketing Expense | 117.57 Cr | 159.43 Cr | 139.16 Cr | 148.11 Cr | — |
| General And Administrative Expense | 81.56 Cr | 103.80 Cr | 103.12 Cr | 129.15 Cr | — |
| Rent And Landing Fees | 0.80 Cr | 0.33 Cr | 0.19 Cr | 0.33 Cr | — |
| Gross Profit | 1.47K Cr | 1.40K Cr | 1.55K Cr | 1.66K Cr | — |
| Cost Of Revenue | 813.06 Cr | 795.23 Cr | 875.65 Cr | 948.03 Cr | — |
| Total Revenue | 2.28K Cr | 2.19K Cr | 2.42K Cr | 2.61K Cr | — |
| Operating Revenue | 2.28K Cr | 2.19K Cr | 2.42K Cr | 2.61K Cr | — |
| Impairment Of Capital Assets | — | — | — | — | -3.10 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Pfizer Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.